

**Amendments to the Claims**

1. (Previously presented) A pharmaceutical composition comprising at least two antigens and a pharmaceutically acceptable carrier, wherein  
each of said antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity response in a mammalian subject;  
the composition is capable of treating a benign epithelial tumor caused by a papilloma virus in a mammalian subject; and  
one of the two antigens is a bacterial antigen and the other is a candida antigen.
- 2-3. Canceled.
4. (Previously presented) The pharmaceutical composition of claim 1 wherein the composition is capable of treating a benign epithelial tumor caused by a human papilloma virus in a human subject.
5. (Previously presented) The pharmaceutical composition of claim 1, wherein said benign epithelial tumor is a verruca, a condyloma, bowenoid papulosis, a laryngeal papilloma, or a epidermodysplasia verruciformis.
6. (Original) The pharmaceutical composition of claim 5, wherein said verruca is verruca vulgaris, verruca plantaris, verruca palmeris or verruca plana.
7. (Original) The pharmaceutical composition of claim 1, wherein said antigens are antigenic determinants, haptens or epitopes of said antigens and are responsible for inducing said delayed type hypersensitivity response in the subject.
8. Canceled.
9. (Withdrawn) The pharmaceutical composition of claim 1 wherein the composition further comprises a trichophyton antigen, a mumps antigen, or a combination thereof.



10. (Withdrawn) The pharmaceutical composition of claim 9, wherein said antigens are a combination of candida, trichophyton and mumps.

11. (Withdrawn) The pharmaceutical composition of claim 1, further comprising at least one cytokine or colony stimulating factor into said tumor.

12. (Withdrawn) The pharmaceutical composition of claim 11, wherein said colony stimulating factor is granulocyte macrophage colony stimulating factor and said cytokine is interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$ , interleukin-2 or interleukin-12.

13-14. Canceled.

15. (Original) A kit comprising at least one container, a hypodermic needle or a high pressure injection device, and the pharmaceutical composition of claim 1.

16. (Withdrawn) A kit of claim 15, further comprising at least one container, a hypodermic needle or a high pressure injection device comprising at least one additional pharmaceutical composition comprising at least one cytokine or colony stimulating factor into said tumor.

17. (Withdrawn) A kit comprising at least one container, a hypodermic needle or a high pressure injection device comprising the pharmaceutical composition of claim 11.

18-32. Canceled.

33. (Previously presented) The pharmaceutical composition of claim 1, wherein said pharmaceutical composition does not contain an immunogenic additive other than said antigens.

34-35. Canceled.



36. (Previously presented) The pharmaceutical composition of claim 1, wherein one of said antigens is an allergenic *Candida albicans* extract for intradermal testing.

37. (Previously presented) The pharmaceutical composition of claim 36, wherein said allergenic *Candida albicans* extract for intradermal testing is the *Candida albicans* Skin Test Antigen.

38-39. Canceled.

40. (Withdrawn) The pharmaceutical composition of claim 10, wherein said candida antigen is an allergenic *Candida albicans* extract for intradermal testing.

41. (Withdrawn) The pharmaceutical composition of claim 40, wherein said allergenic *Candida albicans* extract for intradermal testing is the *Candida albicans* Skin Test Antigen.

42-45. Canceled.

46. (Withdrawn) The pharmaceutical composition of claim 10, wherein said candida antigen is an allergenic *Candida albicans* extract, said mumps antigen is an allergenic Mumps Skin Test Antigen and said trichophyton antigen is an allergenic trichophyton extract.

47. (Withdrawn) The pharmaceutical composition of claim 46, wherein said allergenic *Candida albicans* extract for intradermal testing is the *Candida albicans* Skin Test Antigen.

48. (New) The pharmaceutical composition of claim 1 wherein humans have a preexisting sensitivity to each of said antigens such that each of said antigens, when injected intradermally into a human subject, induces a cutaneous delayed type hypersensitivity response in at least some human subjects.



49. (New) The pharmaceutical composition of claim 48 wherein each of said antigens induces a cutaneous delayed type hypersensitivity response in most healthy human subjects.

50. (New) The pharmaceutical composition of claim 1 wherein each of said antigens has a high prevalence of reactivity in humans or another mammal to induce a cutaneous delayed type hypersensitivity response.

51. (New) The pharmaceutical composition of claim 1 wherein each of said antigens is an antigen from a naturally occurring infectious agent.